AgingResearch.NewsJoin free

Ibutamoren

Intervention

1 paper2 findings

PubChem 178024

C, W, M, H: cells, worms or flies, mice, humans. Dark: independent labs found the same change there. Light: one lab or one study. Outline: nothing yet.

Labs are independent when their papers share no last author and no institution.

Against: findings that point the other way from most findings on the same outcome.

On aging: the drug’s trials ARN judged to be about aging, of every trial that tests it for any use.

No results posted: trials that ended more than a year ago with no results on ClinicalTrials.gov and no paper in ARN’s record.

Company ties: findings with an author at a company, or from a paper whose competing-interests statement declares ties to one.

  • 1 lab in 1 country
  • 2 of 2 findings with company ties
  • Human trial1

Outcomes

2

Fat-free mass

upin humans1

1 study

  1. Ibutamoren increases fat-free mass in humans (median +1 kg vs -0.1 kg on placebo).

    “FFM increased in the IB group (median +1, range -2.7 to +4.1kg) but not on placebo (-0.1, -3.7 to +2.9kg), p<0.001.”

    Human trialhealthy older adultsoral25 mg once daily6 monthsn = 43

    SUN-658 Ibutamoren Mesylate, an Oral Growth Hormone (GH) Secretagogue, Modifies Body Composition in Healthy Older Adults by Increasing Both the Amount and the Pattern of Endogenous GH Secretion

    ENDO 2025 abstract22 Oct 2025

Growth hormone

upin humans1

1 study

  1. Ibutamoren increases growth hormone in humans (median change +23 μg/L over 24hr vs +2.3 on placebo).

    “total GH production increased in the IB-treated group (median change +23, range -21 to 92 μg/L over 24hr) but not on placebo”

    Human trialhealthy older adultsoral25 mg once daily6 monthsn = 43

    SUN-658 Ibutamoren Mesylate, an Oral Growth Hormone (GH) Secretagogue, Modifies Body Composition in Healthy Older Adults by Increasing Both the Amount and the Pattern of Endogenous GH Secretion

    ENDO 2025 abstract22 Oct 2025

More on Growth hormone

Latest

Related